Podcast: What Does The Pfizer/Seagen Merger Mean For M&A In 2023?
A Discussion Of Current Deal Trends
Scrip overviews biopharma deal-making in 2022 and discusses the Pfizer/Seagen merger and its ramifications for the remainder of 2023, with EF Hutton analyst Mike King and Mintz attorney Matt Gardella.
